Literature DB >> 3142079

Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.

R B Francis1, W G McGehee, D I Feinstein.   

Abstract

To investigate the hypothesis that diminished endothelial fibrinolytic activity contributes to the pathogenesis of thrombosis in patients with the lupus anticoagulant (LA), we assessed the ability of endothelium to release tissue-type plasminogen activator (t-PA) in response to standardized venous occlusion (VO) of the arm, and the extent of inhibition of t-PA, in 11 subjects with LA and a history of thrombosis and in 36 healthy normal subjects. The mean rise in plasma t-PA antigen after VO, the mean plasma free t-PA activity after VO, and the mean plasma t-PA inhibitor level prior to VO were not significantly different in subjects with LA and thrombosis and in normal subjects. Four subjects with LA and thrombosis (36%), and five of 36 healthy control subjects (14%) generated no detectable free t-PA activity after VO ("non-responders"); this difference was not statistically significant. All four "non-responders" with LA and thrombosis had normal t-PA antigen release after VO, indicating that the lack of detectable free t-PA activity after VO was due to increased inhibition of released t-PA. We conclude that abnormally reduced endothelial fibrinolytic activity is not present in the majority of subjects with LA and thrombosis. In the subset of subjects with LA and thrombosis who generate no detectable t-PA activity after VO, a stimulatory effect of LA on endothelial production of t-PA inhibitor cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142079

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

Review 1.  The antiphospholipid antibody dilemma.

Authors:  R H Derksen; P Hasselaar; J D Oosting; P G De Groot
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

Review 2.  Antiphospholipid antibodies and the antiphospholipid syndrome.

Authors:  E N Harris; S S Pierangeli
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein.

Authors:  L R Sammaritano; A E Gharavi; C Soberano; R A Levy; M D Lockshin
Journal:  J Clin Immunol       Date:  1992-01       Impact factor: 8.317

4.  Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3.

Authors:  P Fishman; E Falach-Vaknine; R Zigelman; R Bakimer; B Sredni; M Djaldetti; Y Shoenfeld
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

5.  Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy.

Authors:  A Doria; A Ghirardello; M Boscaro; M L Viero; E Vaccaro; G M Patrassi; P F Gambari
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.